By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Vitamins > Doxercalciferol (oral/injection) > Doxercalciferol Dosage
Vitamins
https://themeditary.com/dosage-information/doxercalciferol-dosage-10225.html

Doxercalciferol Dosage

Drug Detail:Doxercalciferol (oral/injection) (Doxercalciferol (oral/injection) [ dock-sir-kal-sih-fer-all ])

Drug Class: Vitamins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Secondary Hyperparathyroidism

Intravenous dosing for patients on dialysis:
Initial dose:

  • Intact parathyroid hormone (iPTH) over 400 pg/mL: 4 mcg IV 3 times per week at the end of dialysis, or approximately every other day
Maintenance dose:
  • iPTH decreased less than 50% AND above 300 pg/mL: increase 1 to 2 mcg every 8 weeks as needed
  • iPTH decreased more than 50% AND above 300 pg/mL: maintain previous dose
  • iPTH 150 to 300 pg/mL: maintain previous dose
  • iPTH below 100 pg/mL: suspend dosing for 1 week, then resume at a dose at least 1 mcg lower
  • Doses higher than 18 mcg weekly have not been studied

Oral dosing for patients on dialysis:
Initial dose:
  • iPTH over 400 pg/mL: 10 mcg orally 3 times per week at the end of dialysis, or approximately every other day
Maintenance dose:
  • iPTH decreased less than 50% AND above 300 pg/mL: increase 2.5 mcg every 8 weeks as needed
  • iPTH 150 to 300 pg/mL: maintain previous dose
  • iPTH below 100 pg/mL: suspend dosing for 1 week, then resume at a dose at least 2.5 mcg lower
Maximum dose: 20 mcg, orally, three times a week

Oral dosing, pre-dialysis, Stage 3 or 4 Chronic Kidney Disease (CKD):
Initial dose:
  • iPTH over 70 pg/mL (Stage 3 CKD): 1 mcg, orally, once a day
  • iPTH over 110 pg/mL (Stage 4 CKD): 1 mcg, orally, once a day
Maintenance dose:
  • iPTH over 70 pg/mL (Stage 3 CKD): increase by 0.5 mcg at 2 week intervals, as needed
  • iPTH over 110 pg/mL (Stage 4 CKD): increase by 0.5 mcg at 2 week intervals, as needed
  • iPTH 35 to 70 pg/mL (Stage 3 CKD): maintain previous dose
  • iPTH 70 to 110 pg/mL (Stage 4 CKD): maintain previous dose
  • iPTH below 35 pg/mL (Stage 3 CKD): suspend dosing for 1 week, then resume at a dose at least 0.5 mcg lower
  • iPTH below 70 pg/mL (Stage 4 CKD): suspend dosing for 1 week, then resume at a dose at least 0.5 mcg lower
Maximum dose: 3.5 mcg orally once a day

Comments:
  • Individualize dosing based on iPTH levels with monitoring of serum calcium and phosphorus.
  • Reduce dose or suspend treatment for hypercalcemia, hyperphosphatemia, or a serum calcium times phosphorus product greater than 55 mg(2)/dL(2).

Uses: Treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, or patients with Stage 3 or 4 chronic kidney disease.

Renal Dose Adjustments

See Usual Adult Dose

Data not available for Stage 2 chronic kidney disease

Liver Dose Adjustments

Use with caution.

  • More frequent monitoring of intact parathyroid hormone (iPTH), calcium, and phosphorus levels is recommended.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

See Usual Adult Dose

Other Comments

Storage requirements:

  • Store at controlled room temperature (77F).

Monitoring:
  • Determine serum calcium, phosphorus, and iPTH prior to treatment.
  • Weekly monitoring of serum calcium, phosphorus, and iPTH is recommended during treatment of dialysis patients.
  • Every other week monitoring of serum calcium, phosphorus, and iPTH is recommended during treatment initiation and dose adjustments in pre-dialysis patients; monitor monthly for 3 months once stabilized, then every 3 months thereafter.

Patient advice:
  • Advise patients and caregivers about adherence to diet, calcium supplementation, and avoidance of nonprescription drugs without physician approval.
  • Inform patients of the symptoms of hypercalcemia.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by